Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT02970318
Previous Study | Return to List | Next Study

A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02970318
Recruitment Status : Active, not recruiting
First Posted : November 22, 2016
Last Update Posted : August 16, 2019
Sponsor:
Information provided by (Responsible Party):
Acerta Pharma BV

Brief Summary:
This study is designed to evaluate the efficacy of acalabrutinib compared with rituximab in combination with idelalisib or bendamustine in previously treated subjects with chronic lymphocytic leukemia (CLL).

Condition or disease Intervention/treatment Phase
Chronic Lymphocytic Leukemia Drug: Acalabrutinib (ACP-196) Drug: Rituximab Drug: Idelalisib Drug: Bendamustine Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 306 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Multicenter, Open-Label, Phase 3 Study of Acalabrutinib (ACP-196) Versus Investigator's Choice of Either Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Subjects With R/R Chronic Lymphocytic Leukemia
Actual Study Start Date : February 28, 2017
Actual Primary Completion Date : January 15, 2019
Estimated Study Completion Date : March 2020


Arm Intervention/treatment
Experimental: Acalabrutinib (ACP-196)
Acalabrutinib (ACP-196) Monotherapy
Drug: Acalabrutinib (ACP-196)
Acalabrutinib monotherapy

Active Comparator: Rituximab Plus Idelalisib or Bendamustine
Investigator's Choice of Rituximab Plus Idelalisib or Bendamustine
Drug: Rituximab
Rituximab in combination with idelalisib or bendamustine

Drug: Idelalisib
Idelalisib in combination with rituximab

Drug: Bendamustine
Bendamustine in combination with rituximab




Primary Outcome Measures :
  1. IRC-assessed progression-free survival (PFS) in Arm A compared to Arm B [ Time Frame: 48 months ]

Secondary Outcome Measures :
  1. Investigator-assessed progression-free survival (PFS) in Arm A compared to Arm B [ Time Frame: 48 months ]
  2. Investigator and IRC-assessed overall response rate (ORR) in Arm A compared to Arm B [ Time Frame: 48 months ]
  3. Overall survival (OS) in Arm A compared to Arm B [ Time Frame: 48 months ]
  4. Patient reported outcomes (PROs) in Arm A compared to Arm B [ Time Frame: 48 months ]
  5. Investigator and IRC-assessed duration of response (DOR) in Arm A compared to Arm B [ Time Frame: 48 months ]
  6. Time to next treatment (TTNT) in Arm A compared to Arm B [ Time Frame: 48 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Men and women ≥ 18 years of age.
  • ECOG performance status of 0 to 2.
  • Received ≥ 1 prior systemic therapies for CLL.
  • Diagnosis of CLL - CD-20 positive, and meeting published criteria (Hallek, 2008).
  • Active disease meeting ≥ 1 of the IWCLL 2008 criteria for requiring treatment.
  • Meet the following laboratory parameters:

    • ANC ≥ 750 cells/μL or ≥ 500 cells/μL in subjects with documented bone marrow involvement, and independent of growth factor support 7 days before assessment.
    • Platelet count ≥ 50,000 cells/μL or ≥ 30,000 cells/μL in subjects with documented bone marrow involvement, and without transfusion support 7 days before assessment.
    • AST and ALT ≤ 2.0 x upper limit of normal
    • Total bilirubin ≤ 1.5 x ULN.
    • Estimated creatinine clearance of ≥ 30 mL/min

Exclusion Criteria:

  • Known prolymphocytic leukemia or history of, or currently suspected, Richter's syndrome. Known CNS lymphoma or leukemia.
  • Prior exposure to a BCL-2 inhibitor or B-cell receptor inhibitor.
  • Uncontrolled autoimmune hemolytic anemia or idiopathic thrombocytopenic purpura.
  • Received any chemotherapy, external beam radiation therapy, anticancer antibodies, or investigational drug within 30 days before first dose of study drug.
  • Prior radio- or toxin-conjugated antibody therapy.
  • Major surgery within 30 days of first dose of study drug.
  • Prior malignancy, except for adequately treated lentigo maligna melanoma, non-melanomatous skin cancer, carcinoma in situ or other malignancy treated with no evidence of active disease > 2 years before Screening and at low risk for recurrence.
  • Significant cardiovascular disease within 6 months of screening.
  • Known history of infection with HIV, or any uncontrolled active systemic infection.
  • Active CMV infection.
  • Serologic status reflecting active hepatitis B or C infection.
  • History of or ongoing drug-induced pneumonitis.
  • Malabsorption syndrome, or other condition that would impair absorption of oral study medication.
  • Received a live virus vaccination within 28 days of first dose of study drug.
  • History of stroke or intracranial hemorrhage within 6 months before first dose of study drug.
  • History of bleeding diathesis.
  • Requires or receiving anticoagulation with warfarin or equivalent vitamin K antagonists within 7 days of first dose of study drug.
  • Requires treatment with a strong CYP3A inhibitor/inducer.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02970318


  Hide Study Locations
Locations
Layout table for location information
United States, Illinois
Research Site
Joliet, Illinois, United States, 60435
United States, Nebraska
Research Site
Lincoln, Nebraska, United States, 68506
Australia, New South Wales
Research Site
Gosford, New South Wales, Australia
Research Site
Waratah, New South Wales, Australia
Australia, Queensland
Research Site
Auchenflower, Queensland, Australia
Research Site
Chermside, Queensland, Australia
Research Site
South Brisbane, Queensland, Australia
Research Site
Southport, Queensland, Australia
Australia, South Australia
Research Site
Adelaide, South Australia, Australia
Research Site
Woodville South, South Australia, Australia
Australia, Tasmania
Research Site
Hobart, Tasmania, Australia, 7000
Australia, Victoria
Research Site
Geelong, Victoria, Australia
Research Site
Melbourne, Victoria, Australia
Australia, Western Australia
Research Site
Murdoch, Western Australia, Australia, 6150
Research Site
Nedlands, Western Australia, Australia
Austria
Research Site
Wels, Upper Austria, Austria
Research Site
Wien, Vienna, Austria
Research Site
Salzburg, Austria
Belgium
Research Site
Antwerp, Antwerpen, Belgium
Research Site
Ieper, West-vlaanderen, Belgium
Research Site
Gent, Belgium
Research Site
Yvoir, Belgium
Bulgaria
Research Site
Pleven, Bulgaria
Research Site
Plovdiv, Bulgaria
Research Site
Vratsa, Bulgaria
Canada, Alberta
Research Site
Calgary, Alberta, Canada
Canada, New Brunswick
Research Site
Saint John, New Brunswick, Canada
Canada, Ontario
Research Site
Ottawa, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Canada, Quebec
Research Site
Montréal, Quebec, Canada
Croatia
Research Site
Zagreb, Croatia
Czechia
Research Site
Brno, Jihormoravsky KRAJ, Czechia
Research Site
Olomouc, Olomoucky, Czechia
Research Site
Praha 10, Praha, Czechia
Research Site
Ostrava - Poruba, Severomoravsky KRAJ, Czechia
Research Site
Hradec Kralové, Vychodocesky KRAJ, Czechia
Research Site
Plzen - Lochotin, Czechia
France
Research Site
Bordeaux, Aquitaine, France
Research Site
Brest Cedex, Bretagne, France
Research Site
Paris, Ile-de-france, France
Research Site
Nantes Cedex 1, PAYS DE LA Loire, France
Research Site
Marseille Cedex 9, Provence Alpes COTE D'azur, France
Germany
Research Site
Mutlangen, Baden-wuerttemberg, Germany
Research Site
Aschaffenburg, Bayern, Germany
Hong Kong
Research Site
Hong Kong, Hong Kong
Hungary
Research Site
Gyula, Bekes, Hungary
Research Site
Debrecen, Hajdu-bihar, Hungary
Research Site
Budapest, Hungary
Israel
Research Site
Ashkelon, Ashqelon, Israel
Research Site
Haifa, Israel
Research Site
Jerusalem, Israel
Italy
Research Site
Meldola, Forli-cesena, Italy
Research Site
Bergamo, Lombardia, Italy
Research Site
Aviano, Pordenone, Italy
Research Site
Brescia, Italy
Research Site
Genova, Italy
Research Site
Milano, Italy
Research Site
Modena, Italy
Korea, Republic of
Research Site
Daegu, Chungcheongnam-do, Korea, Republic of
Research Site
Seongnam-si, Gyeonggi-do, Korea, Republic of
Research Site
Incheon, Korea, Republic of
Research Site
Seoul, Korea, Republic of
Research Site
Ulsan, Korea, Republic of
New Zealand
Research Site
Palmerston North, Manawatu-wanganui, New Zealand
Research Site
Christchurch, New Zealand
Poland
Research Site
Bydgoszcz, Kujawsko-pomorskie, Poland
Research Site
Łódź, Lodzkie, Poland
Research Site
Lublin, Lubelskie, Poland
Research Site
Kraków, Malopolskie, Poland
Research Site
Brzozow, Podkarpackie, Poland
Research Site
Białystok, Podlaskie, Poland
Research Site
Gdańsk, Pomorskie, Poland
Russian Federation
Research Site
Sochi, Krasnodar, Russian Federation
Research Site
Ryazan, Ryazanr, Russian Federation
Research Site
St. Petersburg, Saint Petersburg, Russian Federation
Research Site
Ekaterinburg, Sverdlovsk, Russian Federation
Research Site
Yaroslavl, Yaroslavlr, Russian Federation
Research Site
Penza, Russian Federation
Research Site
Tula, Russian Federation
Research Site
Volgograd, Russian Federation
Singapore
Research Site
Singapore, Singapore
Slovakia
Research Site
Bratislava, Slovakia
Research Site
Košice, Slovakia
Spain
Research Site
Badalona, Barcelona, Spain
Research Site
Majadahonda, Madrid, Spain
Research Site
Madrid, Spain
Research Site
Salamanca, Spain
Research Site
Santander, Spain
Research Site
Valencia, Spain
Sweden
Research Site
Borås, Västra Götaland, Sweden
Research Site
Luleå, Sweden
Research Site
Stockholm, Sweden
Taiwan
Research Site
Hualien City, Taiwan
Ukraine
Research Site
Kyiv, Kiev, Ukraine
Research Site
Cherkasy, Ukraine
Research Site
Dnipropetrovsk, Ukraine
Research Site
Ivano-Frankivsk, Ukraine
Research Site
Khmelnytskyi, Ukraine
Research Site
Kiev, Ukraine
Research Site
Zhytomyr, Ukraine
United Kingdom
Research Site
Birmingham, England, United Kingdom
Research Site
Cambridge, England, United Kingdom
Research Site
Canterbury, England, United Kingdom
Research Site
Leicester, England, United Kingdom
Research Site
London, England, United Kingdom
Research Site
Manchester, England, United Kingdom
Research Site
Southampton, England, United Kingdom
Research Site
Wolverhampton, England, United Kingdom
Sponsors and Collaborators
Acerta Pharma BV
Investigators
Layout table for investigator information
Study Director: Acerta Clinical Trials 1-888-292-9613; acertamc@dlss.com

Layout table for additonal information
Responsible Party: Acerta Pharma BV
ClinicalTrials.gov Identifier: NCT02970318     History of Changes
Other Study ID Numbers: ACE-CL-309
First Posted: November 22, 2016    Key Record Dates
Last Update Posted: August 16, 2019
Last Verified: August 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Acerta Pharma BV:
CLL
BTK
Bruton Tyrosine Kinase
acalabrutinib
ACP-196
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia
Leukemia, Lymphoid
Leukemia, Lymphocytic, Chronic, B-Cell
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Leukemia, B-Cell
Rituximab
Bendamustine Hydrochloride
Idelalisib
Antineoplastic Agents, Immunological
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Enzyme Inhibitors